<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737541</url>
  </required_header>
  <id_info>
    <org_study_id>83/11</org_study_id>
    <nct_id>NCT01737541</nct_id>
  </id_info>
  <brief_title>Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage</brief_title>
  <acronym>FMRICH</acronym>
  <official_title>Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): a Randomised Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autónoma de Aguascalientes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autónoma de Aguascalientes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter clinical trial that will
      be carried out in Mexico. The purpose of this study is to test whether a 3-month treatment
      with fluoxetine enhances motor recovery in non-depressed patients with acute intracerebral
      hemorrhage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spontaneous, nontraumatic intracerebral hemorrhage (ICH) is a subtype of stroke that causes a
      great amount of disability, economic and social burden. This is particularly true in
      developing countries where it accounts for between 20% and 50% of all strokes.
      Pharmacological and surgical interventions have been attempted to diminish the mortality and
      disability derived from ICH, with unsuccessful results. Recently the use of Fluoxetine in
      addition to physical rehabilitation has been proven useful to improve motor recovery from
      cerebral infarct. The purpose of this study is to test whether a 3-month treatment with
      fluoxetine enhances motor recovery in non-depressed patients with acute intracerebral
      hemorrhage.

      This is a randomized, double-blind, placebo-controlled, multicenter clinical trial. This
      trial will recruit 86 patients with intracerebral hemorrhage of both sexes, ages &gt;18 years,
      from four Mexican hospitals. The patients will receive either 20mg of fluoxetine or a placebo
      once daily for 90 days. The primary outcome is the mean change in Fugl-Meyer Motor Scale
      score between inclusion (day 0) and day 90. The secondary outcomes will be changes in Barthel
      Index, Modified Rankin scale and National Institutes of Health (NIH) Stroke Scale. The
      outcomes will be measured at day 45±7days and at day 90, for a total of four visits with each
      subject (at screening and at 0, 45 and 90days).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study recruitment was suspended due to lack of funding
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fugl Meyer Motor Scale score</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Change from Baseline in Fugl Meyer Motor Scale score at 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Change from Baseline in Barthel Index at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Change from Baseline in modified Rankin Scale at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Stroke Scale</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Change from Baseline in NIH Stroke Scale at 90 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Motor Impairment</condition>
  <arm_group>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluoxetine per os 20 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>per os daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <arm_group_label>Fluoxetine</arm_group_label>
    <other_name>Fluoxac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who had an acute intracerebral hemorrhage within the past 10 days causing
             hemiparesis or hemiplegia

          -  Fugl-Meyer motor scale (FMMS) scores of 55 or less

          -  Written informed consent for participation in the trial

        Exclusion Criteria:

          -  Severe post-stroke disability (National Institutes of Health stroke scale [NIHSS]
             score &gt;20)

          -  Premorbid disability, evidenced by residual motor deficit from a previous stroke

          -  Comprehension deficit or severe aphasia

          -  Previous diagnosis of depression or one of the following:

               -  Hospital Anxiety and Depression Scale score ≥11 points

               -  Taking antidepressant drugs two weeks before inclusion

          -  Taking neuroleptic drugs or benzodiazepines two weeks before inclusion

          -  Other major diseases with life expectancy less than 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan M Marquez-Romero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autónoma de Aguascalientes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angel A Arauz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Nacional de Neurología y Neurocirugía</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Alta Especialidad Dr. Juan Graham Casasus</name>
      <address>
        <city>Villahermosa</city>
        <state>Tabasco</state>
        <zip>86126</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Zona #1</name>
      <address>
        <city>Aguascalientes</city>
        <zip>202301</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Neurología y Neurocirugía</name>
      <address>
        <city>Mexico City</city>
        <zip>14269</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.trialsjournal.com/content/14/1/77</url>
    <description>Full text protocol</description>
  </link>
  <reference>
    <citation>Marquez-Romero JM, Arauz A, Ruiz-Sandoval JL, Cruz-Estrada Ede L, Huerta-Franco MR, Aguayo-Leytte G, Ruiz-Franco A, Silos H. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials. 2013 Mar 19;14:77. doi: 10.1186/1745-6215-14-77.</citation>
    <PMID>23510124</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>August 20, 2014</last_update_submitted>
  <last_update_submitted_qc>August 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autónoma de Aguascalientes</investigator_affiliation>
    <investigator_full_name>Juan Manuel Marquez-Romero</investigator_full_name>
    <investigator_title>Profesor Investigador</investigator_title>
  </responsible_party>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>Serotonin Uptake Inhibitors</keyword>
  <keyword>Therapeutic Uses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

